Fig. 2: Survival plots. | BJC Reports

Fig. 2: Survival plots.

From: A Phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer

Fig. 2

a Overall survival in the study population, b Overall survival by PD-L1 status, c Progression-free survival in the study population, d Progression-free survival by PD-L1 status. Analysis set: Full analysis set. 1 month = 30.4375 days. CI confidence interval, CPS combined positive score, PDL-1 programmed death-ligand 1. The analysis by PD-L1 status was done for 30 patients whose CPS data were available. The 95% CIs were estimated using the Kaplan–Meier method.

Back to article page